NASDAQ:SNDX

Syndax Pharmaceuticals (SNDX) Stock Forecast, Price & News

$16.26

-0.05 (-0.31%)

(As of 09/21/2023 ET)

Compare

Today's Range: $16.07
▼
$16.50
50-Day Range: $16.26
▼
$21.77
52-Week Range: $16.07
▼
$29.86

Volume: 789,744 shs
Average Volume: 824,571 shs
Market Capitalization: $1.13 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.00

Syndax Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 121.4% Upside
$36.00 Price Target
Short Interest: Bearish
10.02% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: 0.58
Based on 2 Articles This Week
Insider Trading: Selling Shares
$3.74 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.94) to ($2.85) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

230th out of 965 stocks

Pharmaceutical Preparations Industry

92nd out of 445 stocks

4.5

Analyst's Opinion

Consensus Rating
Syndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $36.00, Syndax Pharmaceuticals has a forecasted upside of 121.4% from its current price of $16.26.
Amount of Analyst Coverage
Syndax Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
10.02% of the outstanding shares of Syndax Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 8.8.
Change versus previous month
Short interest in Syndax Pharmaceuticals has recently decreased by 2.79%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Syndax Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Syndax Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Syndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Syndax Pharmaceuticals is -1.12.

2.0

News and Social Media Coverage

News Sentiment
Syndax Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Syndax Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
5 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,742,083.00 in company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Syndax Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($2.94) to ($2.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Syndax Pharmaceuticals is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syndax Pharmaceuticals is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Syndax Pharmaceuticals has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

SNDX Price History

30 days | 90 days | 365 days | Advanced Chart

SNDX Stock News Headlines

September 20, 2023 | benzinga.com

Looking At Syndax Pharmaceuticals's Recent Unusual Options Activity

September 13, 2023 | americanbankingnews.com

Traders Purchase High Volume of Put Options on Syndax Pharmaceuticals (NASDAQ:SNDX)

September 22, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

September 8, 2023 | seekingalpha.com

Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results

August 31, 2023 | finance.yahoo.com

Syndax Announces Participation at the Citi 18th Annual BioPharma Conference

August 16, 2023 | msn.com

JP Morgan Maintains Syndax Pharmaceuticals (SNDX) Overweight Recommendation

August 8, 2023 | markets.businessinsider.com

Syndax Pharmaceuticals (SNDX) Gets a Buy from Robert W. Baird

August 4, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)

September 22, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 3, 2023 | finance.yahoo.com

Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

August 2, 2023 | msn.com

Syndax Pharmaceuticals (SNDX) Price Target Increased by 8.43% to 37.29

July 28, 2023 | msn.com

Scotiabank Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Sector Outperform Recommendation

July 27, 2023 | markets.businessinsider.com

What 7 Analyst Ratings Have To Say About Syndax Pharmaceuticals

July 27, 2023 | msn.com

Barclays Maintains Syndax Pharmaceuticals (SNDX) Overweight Recommendation

July 25, 2023 | finance.yahoo.com

Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023

July 24, 2023 | msn.com

HC Wainwright & Co. Reiterates Syndax Pharmaceuticals (SNDX) Buy Recommendation

July 24, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Syndax Pharmaceuticals (SNDX)

July 24, 2023 | finance.yahoo.com

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

July 11, 2023 | markets.businessinsider.com

Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape

July 11, 2023 | msn.com

Guggenheim Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy Recommendation

June 30, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Accolade (ACCD)

June 27, 2023 | msn.com

BTIG Maintains Syndax Pharmaceuticals (SNDX) Buy Recommendation

June 26, 2023 | benzinga.com

BTIG Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $35

June 26, 2023 | markets.businessinsider.com

BTIG Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)

June 8, 2023 | seekingalpha.com

Syndax Pharmaceuticals: Precision Oncology Leveraging Strong Financials And R&D

May 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Premier (PINC)

May 12, 2023 | msn.com

Citigroup Maintains Syndax Pharmaceuticals (SNDX) Buy Recommendation

See More Headlines

Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Company Calendar

Last Earnings: 8/03/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNDX
CUSIP: N/A
CIK: 1395937
Web: www.syndax.com
Phone: (781) 419-1400
Fax: 781-419-1420
Employees: 107
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $36.00
High Stock Price Forecast: $42.00
Low Stock Price Forecast: $33.00
Forecasted Upside/Downside: +121.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-149,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -39.08%
Return on Assets: -36.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.56
Quick Ratio: 13.56

Sales & Book Value

Annual Sales: $139.71 million
Price / Sales: 8.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.76 per share
Price / Book: 2.10

Miscellaneous

Outstanding Shares: 69,480,000
Free Float: 66,218,000
Market Cap: $1.13 billion
Optionable: Optionable
Beta: 1.13

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Michael A. Metzger M.B.A. (Age 52)
CEO & Director
Comp: $1.05M

Mr. Keith Alan Goldan CPA (Age 52)
CFO, Treasurer & Chief Accounting Officer
Comp: $649.07k

Mr. Luke J. Albrecht (Age 43)
Sr. VP, Gen. Counsel & Sec.
Comp: $605.82k

Dr. Catherine Madigan M.D. (Age 51)
Chief Medical Officer
Comp: $764.41k

Mr. Steve M. Sabus (Age 57)
Chief Commercial Officer
Comp: $523.44k

Dr. Peter Ordentlich B.Sc. (Age 54)
Ph.D., Co-Founder & Chief Scientific Officer

Dr. Richard A. Heyman Ph.D. (Age 66)
Co-Founder

Dr. Ronald M. Evans Ph.D.
Co-Founder, Advisor and Chair of Scientific Advisory Board

Dr. Michael Downes Ph.D.
Co-Founder

Sharon Klahre
VP of Investor Relations & Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SNDX Stock - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings or view top-rated stocks.
What is Syndax Pharmaceuticals' stock price forecast for 2023?: 9 Wall Street research analysts have issued 1-year price targets for Syndax Pharmaceuticals' shares. Their SNDX share price forecasts range from $33.00 to $42.00. On average, they anticipate the company's stock price to reach $36.00 in the next year. This suggests a possible upside of 121.4% from the stock's current price.
View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts.
How have SNDX shares performed in 2023?: Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of 2023. Since then, SNDX stock has decreased by 36.1% and is now trading at $16.26.
View the best growth stocks for 2023 here.
When is Syndax Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our SNDX earnings forecast.
How were Syndax Pharmaceuticals' earnings last quarter?: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. During the same quarter in the previous year, the firm posted ($0.62) EPS.
What ETFs hold Syndax Pharmaceuticals' stock?: ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK).
What other stocks do shareholders of Syndax Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?: (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
What is Syndax Pharmaceuticals' stock symbol?: Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
Who are Syndax Pharmaceuticals' major shareholders?: Syndax Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.18%), State Street Corp (5.98%), Kynam Capital Management LP (4.69%), Jennison Associates LLC (3.66%), Geode Capital Management LLC (1.90%) and Point72 Asset Management L.P. (1.78%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury.
View institutional ownership trends.
How do I buy shares of Syndax Pharmaceuticals?: Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Syndax Pharmaceuticals' stock price today?: One share of SNDX stock can currently be purchased for approximately $16.26.
How much money does Syndax Pharmaceuticals make?: Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.13 billion and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.
How many employees does Syndax Pharmaceuticals have?: The company employs 107 workers across the globe.
How can I contact Syndax Pharmaceuticals?: Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420.

This page (NASDAQ:SNDX) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial